APAC CIO Outlook
  • Home
  • CXO Insights
  • CIO Views
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • About us
Apac
  • Admired Tech

    Agile

    AI Healthcare

    Artificial Intelligence

    Augmented Reality

    Aviation

    Big Data

    Blockchain

    Cloud

    Cryptocurrency

    Cyber Security

    Digital Transformation

    Drone

    HPC

    Infrared

    Internet of Things

    Networking

    PropTech

    Remote Work

    Scheduling Software

    Simulation

    Startup

    Storage

    Wireless

  • Banking

    E-Commerce

    Education

    FinTech

    Food and Beverages

    Healthcare

    Insurance

    Legal

    Manufacturing

    Pharma and Life Science

    Retail

    Travel and Hospitality

  • Atlassian

    CISCO

    Microsoft

    Oracle

    Salesforce

    SAP

    ServiceNow

  • Business Intelligence

    CEM

    Cloud-based Planning

    Cognitive

    Compliance

    Contact Center

    Contact Tracing

    Contactless Payments

    Content Management System

    Corporate Finance

    CRM

    Custom Software Development

    Data Center

    Enterprise Architecture

    Enterprise Communications

    Enterprise Contract Management

    ERP

    Field Service

    HR Technology

    IT Service Management

    Managed Services

    Procurement

    Product Management

    RegTech

    Revenue Management

    Sales Tech

Menu
    • Augmented Reality
    • Agile
    • Cognitive
    • Cyber Security
    • Digital Transformation
    • Atlassian
    • E-Commerce
    • Managed Services
    • RegTech
    • CISCO
    • Blockchain
    • IoT
    • MORE
    #

    Apac CIO Outlook Weekly Brief

    ×

    Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Apac CIO Outlook

    Subscribe

    loading

    THANK YOU FOR SUBSCRIBING

    • Home
    • News
    • Healthcare
    Editor's Pick (1 - 4 of 8)
    left
    Technology’s Role in The Care and Quality of Life for The Aged

    Jose A Perez, Chief Information Officer, Hammondcare

    Digital Transformation - The Right Way

    Amit Goel, CIO, Metropolis Healthcare

    The (E-) Doctor Is In: What Trends to Spot in Healthcare Technology Today

    Dickon Smart-Gill, CIO, Bumrungrad International Hospital

    Analytics and AI in Healthcare

    Steven Parrish, CIO, Taranaki District Health Board

    Document Management in the Cloud

    Alex Choy, EVP R&D CIO, Change Healthcare

    China Embracing Connected Health

    Geoff Feakes, Group CIO, Tunstall Healthcare

    How Healthy is Your IT?

    John Sutherland-CIO-Ramsay Health Care

    Enterprise Architecture - An Extremely Valuable Discipline for Great Businesses

    Ken Spangler, SVP & CIO FedEx Ground and FedEx Freight, FedEx Services IT

    right

    Lipidor Agrees Terms with Cadila Pharmaceuticals for Phase III Study

    By Apac CIO Outlook | Tuesday, July 14, 2020
    Tweet

    The study is aimed at demonstrating the equivalent therapeutic efficacy with existing medicines for mild to moderate psoriasis.

    FREMONT, CA: Lipidor AB, entered into an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to commence in the first quarter of 2021 with final reporting in the first quarter of 2022. AKP-02 is an antipsoriasis medicine that combines the active substances calcipotriol and betamethasone with Lipidor's spray-based AKVANO technology. In 2017, the market for combination drugs reached USD 580 million per year, and Lipidor is looking to capitalize on the same and stake claim to a significant market share when the drug reaches the market.

    "We're very pleased to announce that we have entered into an agreement to carry out a registration-based Phase III study for AKP-02, Lipidor's combination drug candidate against psoriasis. Through the successful Phase III study for AKP-01, Cadila has shown that they can effectively recruit patients, administer dosing and report clinical study results. The experience of AKP-01 means that we have high hopes for effective cooperation and a successful study," said Ola Holmlund, Lipidor CEO. Lipidor previously announced its intentions to conduct an entirely self-funded Phase III study with the drug candidate AKP-02 in May 2020. An agreement has now been reached with Cadila Pharmaceuticals for the implementation of the study.

    The company highlighted that the Phase III study will involve 270 patients and will be conducted in India on patients with various skin types. The study is aimed at demonstrating the equivalent therapeutic efficacy with existing medicines for mild to moderate psoriasis. The observer-blind and placebo-controlled trial is scheduled to be completed in the fourth quarter of 2021. Lipidor has already collaborated with Cadila regarding the drug candidate AKP-01, and this new agreement now strengthens that cooperation. Lipidor's existing funds will cover the cost of the Phase III study.

    "The market has shown great interest in AKP-02 and by self-funding the implementation of the Phase III study, we will maximize the benefits of later out-licensing. We continue to see great potential in our first drug candidate AKP-01, and the opportunity to now discuss AKP-01 and AKP-02 in a package makes us an even more attractive partner for pharmaceutical companies that can take our products through registration for sale," concluded Ola Holmlund.

    tag

    Pharmaceutical

    Weekly Brief

    loading

    Featured Vendor

    • Green Radar: Delivering All-round Email Security
      Green Radar: Delivering All-round Email Security
    Top 10 Cyber Security Service/Consulting Companies - 2020
    Top 10 Cyber Security  Companies - 2020
    ON THE DECK

    Cyber Security 2020

    Top Vendors

    Cyber Security 2019

    Top Vendors

    Previous Next

    I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

    Read Also

    Technology Trends that Bring Revolutionary Changes in the Way Education Imparted Before

    Technology Trends that Bring Revolutionary Changes in the Way Education Imparted Before

    What Is the Role of AI in Managed Services?

    What Is the Role of AI in Managed Services?

    Four Mistakes to Avoid when Implementing Digital Transformation

    Four Mistakes to Avoid when Implementing Digital Transformation

    How Edge Computing will Address IoT Challenges?

    How Edge Computing will Address IoT Challenges?

    What Are the Differences Between AI and Cognitive Computing?

    What Are the Differences Between AI and Cognitive Computing?

    The Importance of AIOps in Digital Transformation Journey

    The Importance of AIOps in Digital Transformation Journey

    Loading...

    Copyright © 2021 APAC CIOoutlook. All rights reserved. Registration on or use of this site constitutes acceptance of our Terms of Use and Privacy and Anti Spam Policy 

    |  Sitemap |  Subscribe

    follow on linkedinfollow on twitter follow on rss
    This content is copyright protected

    However, if you would like to share the information in this article, you may use the link below:

    https://www.apacciooutlook.com/news/lipidor-agrees-terms-with-cadila-pharmaceuticals-for-phase-iii-study-nwid-7570.html